OPKO Health director receives 50,000 stock options

OPKO HEALTH, INC. director Uppaluri Subbarao V received a grant of stock options covering 50,000 shares of common stock.

Accepted by SEC EDGAR 03/20/2026 - 04:16 PM EDT

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

OPKO HEALTH, INC. director Uppaluri Subbarao V received a grant of stock options covering 50,000 shares of common stock. The options have an exercise price of $1.17 per share and were awarded at no cost to the director. According to the filing, these options become exercisable on March 18, 2027 and expire on March 17, 2036. Following this grant, the director holds stock options for 50,000 underlying shares.

Insider Trade Summary

Grant/Award: 50,000 shares

Grant/Award 1 txn

Insider UPPALURI SUBBARAO V

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	50,000	$0.00	$0.00

Holdings After Transaction: Stock Option (Right to Buy) — 50,000 contracts (Direct)

Holdings Before and After: Stock Option (Right to Buy), 0 to 50,000 contracts (Direct)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did OPKO Health (OPK) disclose for Uppaluri Subbarao V?

OPKO Health reported that director Uppaluri Subbarao V received a grant of stock options for 50,000 shares of common stock. The options were awarded at no cost and provide the right to buy shares at a fixed exercise price of $1.17 per share.

How many OPKO Health shares are covered by the new stock option grant?

The stock option grant to director Uppaluri Subbarao V covers 50,000 underlying shares of OPKO Health common stock. These options give the right, but not the obligation, to purchase those shares at the specified exercise price during the option term.

What is the exercise price of the OPKO Health options granted to Uppaluri Subbarao V?

The options granted to Uppaluri Subbarao V have an exercise price of $1.17 per share of OPKO Health common stock. This strike price is the amount the director would pay per share if he chooses to exercise the 50,000 options in the future.

When do Uppaluri Subbarao V’s OPKO Health stock options become exercisable and when do they expire?

The filing states that the stock options become exercisable on March 18, 2027, giving future purchase rights from that date. They carry an expiration date of March 17, 2036, after which any unexercised options will lapse and can no longer be used.

How many OPKO Health stock options does Uppaluri Subbarao V hold after this transaction?

After this grant, Uppaluri Subbarao V holds stock options covering 50,000 shares of OPKO Health common stock. The Form 4 indicates this as the total derivative position following the transaction, reflecting his current option-based exposure reported in this filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

UPPALURI SUBBARAO V

(Last)

(First)

(Middle)

OPKO HEALTH, INC.

4400 BISCAYNE BLVD.

(Street)

MIAMI

FLORIDA

33137

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
OPKO HEALTH, INC. [ OPK ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$1.17	03/18/2026		A		50,000		03/18/2027	03/17/2036	Common Stock	50,000	$0	50,000	D

Explanation of Responses:

	/s/ Subbarao V. Uppaluri	03/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR